Intrahypothalamic injection of the HIV-1 envelope glycoprotein induces fever via interaction with the chemokine system.
Wasting syndrome is a common complication of HIV infection and is marked by progressive weight loss and weakness, often associated with fever. The mechanisms involved in the pathogenesis of these syndromes are not well defined, and neither are the brain areas involved. The present study tests a new hypothesis: that the preoptic anterior hypothalamus (POAH), the main brain area for thermoregulation and fever, has a role in the pathogenesis of fever induced by glycoprotein 120 (gp120), the surface envelope protein used by the HIV to gain access into immune cells, and that the CXC chemokine receptors (CXCR4) that serve as a coreceptor for HIV entry mediate the effect. A sterilized stainless steel C313G cannula guide was implanted into the POAH, and a biotelemetry system was used to monitor the body temperature (Tb) changes. The administration of gp120 into the POAH induced fever in a dose-dependent manner. To demonstrate possible links between the gp120 and CXCR4 in generating the fever, we pretreated the rats with 1,1'-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] octohydrobromide dihydrate (AMD 3100), an antagonist of stromal cell-derived growth factor (SDF)-1alpha/CXCL12, acting at its receptor, CXCR4, 30 min before administration of gp120. AMD 3100 significantly reduced the gp120-induced fever. The present studies show that the presence of HIV-1 envelope glycoprotein gp120 in the POAH provokes fever via interaction CXCR4 pathway.
Benamar
Khalid
K
Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, USA. kbenamar@temple.edu
Addou
Saad
S
Yondorf
Menachem
M
Geller
Ellen B
EB
Eisenstein
Toby K
TK
Adler
Martin W
MW
D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology; D001596:Benzylamines; D001831:Body Temperature / Q000187:drug effects; D000080027:Cyclams; D005334:Fever / Q000139:chemically induced / Q000209:etiology*; D015699:HIV Envelope Protein gp120 / Q000008:administration & dosage / Q000494:pharmacology*; D006571:Heterocyclic Compounds / Q000494:pharmacology; D008297:Male; D008845:Microinjections; D011301:Preoptic Area / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*
D019380:Anti-HIV Agents; D001596:Benzylamines; D000080027:Cyclams; D015699:HIV Envelope Protein gp120; D006571:Heterocyclic Compounds; D019718:Receptors, CXCR4; C514793:gp120 protein, Human immunodeficiency virus 1; C088327:plerixafor